UBP-302

Summary

UBP-302 is a highly selective kainate receptor antagonist used in the study of many neurological processes. It is active at micromolar concentration within an in vitro preparation and specifically targets the GluK1 (iGluR5) subunit of the receptor. This compound was developed at the University of Bristol.[1]

UBP-302
Names
Systematic IUPAC name
2-({3-[(2S)-2-Amino-2-carboxyethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl}methyl)benzoic acid
Identifiers
  • 745055-91-8 checkY
3D model (JSmol)
  • Interactive image
ChEMBL
  • ChEMBL372797 ☒N
ChemSpider
  • 4925720 ☒N
ECHA InfoCard 100.210.061 Edit this at Wikidata
  • 6420161
  • DTXSID80423571 Edit this at Wikidata
  • InChI=1S/C15H15N3O6/c16-11(14(22)23)8-17-6-5-12(19)18(15(17)24)7-9-3-1-2-4-10(9)13(20)21/h1-6,11H,7-8,16H2,(H,20,21)(H,22,23)/t11-/m0/s1 ☒N
    Key: UUIYULWYHDSXHL-NSHDSACASA-N ☒N
  • InChI=1/C15H15N3O6/c16-11(14(22)23)8-17-6-5-12(19)18(15(17)24)7-9-3-1-2-4-10(9)13(20)21/h1-6,11H,7-8,16H2,(H,20,21)(H,22,23)/t11-/m0/s1
    Key: UUIYULWYHDSXHL-NSHDSACABL
  • c1ccc(c(c1)Cn2c(=O)ccn(c2=O)C[C@@H](C(=O)O)N)C(=O)O
Properties
C15H15N3O6
Molar mass 333.296 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

UBP-310 and UBP-316 (ACET) are related N3-substituted willardiine derivatives.[2]

References edit

  1. ^ More, JC; Nistico, R; Dolman, NP; Clarke, VR; Alt, AJ; Ogden, AM; Buelens, FP; Troop, HM; et al. (2004). "Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist". Neuropharmacology. 47 (1): 46–64. doi:10.1016/j.neuropharm.2004.03.005. hdl:11573/514325. PMID 15165833. S2CID 40775500.
  2. ^ Dolman, NP; More, JCA; Alt, A; Knauss, JL; Pentikäinen, OT; Glasser, CR; Bleakman, D; Mayer, ML; Collingridge, GL; Jane, DE (2007-04-05). "Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists". Journal of Medicinal Chemistry. 50 (7): 1558–1570. doi:10.1021/jm061041u. ISSN 0022-2623. PMID 17348638.